Novo Nordisk EVP: Semaglutide can double obesity business in few years

Now that the FDA has approved Novo Nordisk's semaglutide as an injection treatment for obesity, the pharmaceutical company expects to double its sales of obesity drugs.

Novo Nordisk EVP, Head of Development, Martin Holst Lange | Photo: Novo Nordisk / PR

Now that Danish pharmaceutical company Novo Nordisk has an approval from the US Food and Drug Administration (FDA) in place, Novo Nordisk is ready to launch the obesity drug Wegovy on the US market in late June.

The company is already present on the obesity market with the drug Saxenda. It expects that the new product, which uses semaglutide as an injection-based treatment, will increase sales and give Novo Nordisk access to this unexploited market.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Coloplast upgrades growth expectations following acquisition

Medtech firm Coloplast’s Q1 report for 2021/2022 brings a slight upward adjustment of the reported revenue growth outlook due to foreign exchange developments. Coloplast’s acquisition of Atos Medical is expected to contribute around 6 percent to organic growth.

Demant's surgical division loses president of 13 years

Oticon Medical, the implants division at hearing group Demant, is saying goodbye to President Jes Olsen, who is exiting his role in March after having spearheaded the business leg since 2008. Demant CEO Søren Nielsen is stepping in temporarily until a replacement is found.

Hearing aid market in US grew by 37 percent in 2021

Hearing aid manufacturers have had a good year following one of the worst in their recorded history, as sales in the US have gone up by 37 percent. The progress is mainly driven by the recovery of independent retailers, whereas public sales channel Veterans Affairs still lags behind.

Further reading

Related articles

Latest news

See all jobs